Znaczenie kliniczne prawidłowej regeneracji powierzchni oka po operacji zaćmy Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
film łzowy, kwas hialuronowy, miłorząb japoński, operacja zaćmy, zaburzenia powierzchni oka, zespół suchego oka
##plugins.themes.bootstrap3.article.main##
Abstrakt
Częstość występowania zaburzeń powierzchni oka rośnie po zabiegach okulistycznych,w tym po zabiegu usunięcia zaćmy. Ponad 60% pacjentów kierowanych do operacji zaćmy ma nieprawidłowości filmu łzowego. U pacjentów z ryzykiem wystąpienia po operacji objawów zespołu suchego oka wskazane jest podjęcie terapii miejscowej przed zabiegiem. Leczeniem pierwszego rzutu są preparaty sztucznych łez. W przypadku niewystarczającego efektu stosuje się leczenie substancjami modulującymi przebieg zapalny. Ponadto u pacjentów wymagających terapii pozytywny efekt odnosi wdrożenie higieny brzegów powiek. Spośród preparatów sztucznych łez podkreśla się korzyści z zastosowania kwasu hialuronowego o wysokiej masie cząsteczkowej i wyciągu z miłorzębu japońskiego.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Izdebska J, Samelska K. Znaczenie kliniczne prawidłowej regeneracji powierzchni oka po operacji zaćmy. Ophthatherapy [Internet]. 31 marzec 2024 [cytowane 18 maj 2024];00. Dostępne na: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/3057
Numer
Dział
Chirurgia i laseroterapia
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Schuster AK, Nickels S, Pfeiffer N et al. Frequency of cataract surgery and its impact on visual function-results from the German Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol. 2020; 258(10): 2223-31. http://doi.org/10.1007/s00417-020-04770-0.
2. Lee Y, Kim JS, Park UC et al. Recent trends of refractive surgery rate and detailed analysis of subjects with refractive surgery: The 2008-2015 Korean National Health and Nutrition Examination Survey. PLoS ONE. 2021; 16(12): e0261347. http://doi.org/10.1371/journal.pone.0261347.
3. Cumberland PM, Chianca A, Rahi JS; UK Biobank Eyes & Vision Consortium. Laser refractive surgery in the UK Biobank study: Frequency, distribution by sociodemographic factors, and general health, happiness, and social participation outcomes. J Cataract Refract Surg. 2015; 41(11): 2466-75. http://doi.org/10.1016/j.jcrs.2015.05.040.
4. Mencucci R, Vignapiano R, Rubino P et al. Iatrogenic Dry Eye Disease: Dealing with the Conundrum of Post-Cataract Discomfort. A P.I.C.A.S.S.O. Board Narrative Review. Ophthalmol Ther. 2021; 10(2): 211-23. http://doi.org/10.1007/s40123-021-00332-7.
5. Hamed MA, Aldghaimy AH, Mohamed NS et al. The Incidence of Post Phacoemulsification Surgery Induced Dry Eye Disease in Upper Egypt. Clin Ophthalmol. 2022; 16: 705-13. http://doi.org/10.2147/OPTH.S358866.
6. Jing D, Jiang X, Ren X et al. Change Patterns in Corneal Intrinsic Aberrations and Nerve Density after Cataract Surgery in Patients with Dry Eye Disease. J Clin Med. 2022; 11(19): 5697. http://doi.org/10.3390/jcm11195697.
7. Misra SL, Goh YW, Patel DV et al. Corneal microstructural changes in nerve fiber, endothelial and epithelial density after cataract surgery in patients with diabetes mellitus. Cornea. 2015; 34(2): 177-81. http://doi.org/10.1097/ICO.0000000000000320.
8. De Cillà S, Fogagnolo P, Sacchi M et al. Corneal involvement in uneventful cataract surgery: an in vivo confocal microscopy study. Ophthalmologica. 2014; 231(2): 103-10. http://doi.org/10.1159/000355490.
9. Lum E, Corbett MC, Murphy PJ. Corneal Sensitivity After Ocular Surgery. Eye Contact Lens. 2019; 45(4): 226-37. http://doi.org/10.1097/ICL.0000000000000543.
10. Li XM, Hu L, Hu J et al. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007; 26(9 Suppl 1): S16-20. http://doi.org/10.1097/ICO.0b013e31812f67ca.
11. Naderi K, Gormley J, O’Brart D. Cataract surgery and dry eye disease: A review. Eur J Ophthalmol. 2020; 30(5): 840-55. http://doi.org/10.1177/1120672120929958.
12. Craig JP, Nichols KK, Akpek EK et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15: 276-83. http://doi.org/10.1016/j.jtos.2017.05.008.
13. Farrand KF, Fridman M, Stillman IÖ et al. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017; 182: 90-8.
14. Trattler WB, Majmudar PA, Donnenfeld ED et al. The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017; 11: 1423-30. http://doi.org/10.2147/OPTH.S120159.
15. Agarwal S, Srinivasan B, Harwani AA et al. Perioperative nuances of cataract surgery in ocular surface disorders. Indian J Ophthalmol. 2022; 70(10): 3455-64. http://doi.org/10.4103/ijo.IJO_624_22.
16. Priyadarshini K, Sharma N, Kaur M et al. Cataract surgery in ocular surface disease. Indian J Ophthalmol. 2023; 71(4): 1167-75. http://doi.org/10.4103/IJO.IJO_3395_22.
17. Marinho A, Nunes C, Reis S. Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation. Biomolecules. 2021; 11(10): 1518. http://doi.org/10.3390/biom11101518.
18. Litwiniuk M, Krejner A, Speyrer MS et al. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds. 2016; 28(3): 78-88.
19. Guarise C, Acquasaliente L, Pasut G et al. The role of high molecular weight hyaluronic acid in mucoadhesion on an ocular surface model. J Mech Behav Biomed Mater. 2023; 143: 105908. http://doi.org/10.1016/j.jmbbm.2023.105908.
20. Dogru M, Kojima T, Higa K et al. The Effect of High Molecular Weight Hyaluronic Acid and Latanoprost Eyedrops on Tear Functions and Ocular Surface Status in C57/BL6 Mice. J Clin Med. 2023; 12(2): 544. http://doi.org/10.3390/jcm12020544.
21. Park Y, Song JS, Choi CY et al. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. J Ocul Pharmacol Ther. 2017; 33(2): 66-72. http://doi.org/10.1089/jop.2016.0086.
22. Lee JE, Kim S, Lee HK et al. A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome. Sci Rep. 2022; 12(1): 18737. http://doi.org/10.1038/s41598-022-21330-0.
23. Zhao Y, Paule J, Fu C et al. Out of China: Distribution history of Ginkgo biloba L. Taxon. 2010; 59(2): 495-504. http://doi.org/10.1002/tax.592014.
24. Gong W, Chen C, Dobes C et al. Phylogeography of a living fossil: pleistocene glaciations forced Ginkgo biloba L. (Ginkgoaceae) into two refuge areas in China with limited subsequent postglacial expansion. Mol Phylogenet Evol. 2008; 48(3): 1094-105. http://doi.org/10.1016/j.ympev.2008.05.003.
25. Jacobs BP, Browner WS. Ginkgo biloba: a living fossil. Am J Med. 2000; 108(4): 341-2. http://doi.org/10.1016/S0002-9343(00)00290-4.
26. Adebayo OG, Ben-Azu B, Ajayi AM et al. Gingko biloba abrogate lead-induced neurodegeneration in mice hippocampus: involvement of NF-κB expression, myeloperoxidase activity and pro-inflammatory mediators. Biol Trace Elem Res. 2022; 200(4): 1736-49. http://doi.org/10.1007/s12011-021-02790-3.
27. Sahib S, Sharma A, Muresanu DF et al. Nanodelivery of traditional Chinese Gingko Biloba extract EGb-761 and bilobalide BN-52021 induces superior neuroprotective effects on pathophysiology of heat stroke. Prog Brain Res. 2021; 265: 249-315. http://doi.org/10.1016/bs.pbr.2021.06.007.
28. Sereda M, Xia J, Scutt P et al. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. 2022; 11(11): CD013514. http://doi.org/10.1002/14651858.CD013514.pub2.
29. Evans JR. Ginkgo biloba extract for age-related macular degeneration. Cochrane Database Syst Rev. 2013; 2013(1): CD001775. http://doi.org/10.1002/14651858.CD001775.pub2.
30. Mei N, Guo X, Ren Z et al. Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017; 35(1): 1-28. http://doi.org/10.1080/10590501.2016.1278298.
31. Azuma F, Nokura K, Kako T et al. An Adult Case of Generalized Convulsions Caused by the Ingestion of Ginkgo biloba Seeds with Alcohol. Intern Med. 2020; 59(12): 1555-8. http://doi.org/10.2169/internalmedicine.4196-19.
32. Thiagarajan G, Chandani S, Harinarayana Rao S et al. Molecular and cellular assessment of ginkgo biloba extract as a possible ophthalmic drug. Exp Eye Res. 2002; 75(4): 421-30.
33. Gakhramanov FS, Kerimov KT, Dzhafarov AI. Use of natural antioxidants for the correction of changes in general and local parameters of lipid peroxidation and antioxidant defense system during experimental eye burn. Bull Exp Biol Med. 2006; 142(6): 696-9. http://doi.org/10.1007/s10517-006-0454-z.
34. Russo V, Stella A, Appezzati L et al. Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis. Eur J Ophthalmol. 2009; 19(3): 331-6. http://doi.org/10.1177/112067210901900301.
35. Fogagnolo P, Romano D, De Ruvo V et al. Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery. J Ocul Pharmacol Ther. 2022; 38(4): 305-10. http://doi.org/10.1089/jop.2021.0123.
2. Lee Y, Kim JS, Park UC et al. Recent trends of refractive surgery rate and detailed analysis of subjects with refractive surgery: The 2008-2015 Korean National Health and Nutrition Examination Survey. PLoS ONE. 2021; 16(12): e0261347. http://doi.org/10.1371/journal.pone.0261347.
3. Cumberland PM, Chianca A, Rahi JS; UK Biobank Eyes & Vision Consortium. Laser refractive surgery in the UK Biobank study: Frequency, distribution by sociodemographic factors, and general health, happiness, and social participation outcomes. J Cataract Refract Surg. 2015; 41(11): 2466-75. http://doi.org/10.1016/j.jcrs.2015.05.040.
4. Mencucci R, Vignapiano R, Rubino P et al. Iatrogenic Dry Eye Disease: Dealing with the Conundrum of Post-Cataract Discomfort. A P.I.C.A.S.S.O. Board Narrative Review. Ophthalmol Ther. 2021; 10(2): 211-23. http://doi.org/10.1007/s40123-021-00332-7.
5. Hamed MA, Aldghaimy AH, Mohamed NS et al. The Incidence of Post Phacoemulsification Surgery Induced Dry Eye Disease in Upper Egypt. Clin Ophthalmol. 2022; 16: 705-13. http://doi.org/10.2147/OPTH.S358866.
6. Jing D, Jiang X, Ren X et al. Change Patterns in Corneal Intrinsic Aberrations and Nerve Density after Cataract Surgery in Patients with Dry Eye Disease. J Clin Med. 2022; 11(19): 5697. http://doi.org/10.3390/jcm11195697.
7. Misra SL, Goh YW, Patel DV et al. Corneal microstructural changes in nerve fiber, endothelial and epithelial density after cataract surgery in patients with diabetes mellitus. Cornea. 2015; 34(2): 177-81. http://doi.org/10.1097/ICO.0000000000000320.
8. De Cillà S, Fogagnolo P, Sacchi M et al. Corneal involvement in uneventful cataract surgery: an in vivo confocal microscopy study. Ophthalmologica. 2014; 231(2): 103-10. http://doi.org/10.1159/000355490.
9. Lum E, Corbett MC, Murphy PJ. Corneal Sensitivity After Ocular Surgery. Eye Contact Lens. 2019; 45(4): 226-37. http://doi.org/10.1097/ICL.0000000000000543.
10. Li XM, Hu L, Hu J et al. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007; 26(9 Suppl 1): S16-20. http://doi.org/10.1097/ICO.0b013e31812f67ca.
11. Naderi K, Gormley J, O’Brart D. Cataract surgery and dry eye disease: A review. Eur J Ophthalmol. 2020; 30(5): 840-55. http://doi.org/10.1177/1120672120929958.
12. Craig JP, Nichols KK, Akpek EK et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15: 276-83. http://doi.org/10.1016/j.jtos.2017.05.008.
13. Farrand KF, Fridman M, Stillman IÖ et al. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017; 182: 90-8.
14. Trattler WB, Majmudar PA, Donnenfeld ED et al. The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017; 11: 1423-30. http://doi.org/10.2147/OPTH.S120159.
15. Agarwal S, Srinivasan B, Harwani AA et al. Perioperative nuances of cataract surgery in ocular surface disorders. Indian J Ophthalmol. 2022; 70(10): 3455-64. http://doi.org/10.4103/ijo.IJO_624_22.
16. Priyadarshini K, Sharma N, Kaur M et al. Cataract surgery in ocular surface disease. Indian J Ophthalmol. 2023; 71(4): 1167-75. http://doi.org/10.4103/IJO.IJO_3395_22.
17. Marinho A, Nunes C, Reis S. Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation. Biomolecules. 2021; 11(10): 1518. http://doi.org/10.3390/biom11101518.
18. Litwiniuk M, Krejner A, Speyrer MS et al. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds. 2016; 28(3): 78-88.
19. Guarise C, Acquasaliente L, Pasut G et al. The role of high molecular weight hyaluronic acid in mucoadhesion on an ocular surface model. J Mech Behav Biomed Mater. 2023; 143: 105908. http://doi.org/10.1016/j.jmbbm.2023.105908.
20. Dogru M, Kojima T, Higa K et al. The Effect of High Molecular Weight Hyaluronic Acid and Latanoprost Eyedrops on Tear Functions and Ocular Surface Status in C57/BL6 Mice. J Clin Med. 2023; 12(2): 544. http://doi.org/10.3390/jcm12020544.
21. Park Y, Song JS, Choi CY et al. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. J Ocul Pharmacol Ther. 2017; 33(2): 66-72. http://doi.org/10.1089/jop.2016.0086.
22. Lee JE, Kim S, Lee HK et al. A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome. Sci Rep. 2022; 12(1): 18737. http://doi.org/10.1038/s41598-022-21330-0.
23. Zhao Y, Paule J, Fu C et al. Out of China: Distribution history of Ginkgo biloba L. Taxon. 2010; 59(2): 495-504. http://doi.org/10.1002/tax.592014.
24. Gong W, Chen C, Dobes C et al. Phylogeography of a living fossil: pleistocene glaciations forced Ginkgo biloba L. (Ginkgoaceae) into two refuge areas in China with limited subsequent postglacial expansion. Mol Phylogenet Evol. 2008; 48(3): 1094-105. http://doi.org/10.1016/j.ympev.2008.05.003.
25. Jacobs BP, Browner WS. Ginkgo biloba: a living fossil. Am J Med. 2000; 108(4): 341-2. http://doi.org/10.1016/S0002-9343(00)00290-4.
26. Adebayo OG, Ben-Azu B, Ajayi AM et al. Gingko biloba abrogate lead-induced neurodegeneration in mice hippocampus: involvement of NF-κB expression, myeloperoxidase activity and pro-inflammatory mediators. Biol Trace Elem Res. 2022; 200(4): 1736-49. http://doi.org/10.1007/s12011-021-02790-3.
27. Sahib S, Sharma A, Muresanu DF et al. Nanodelivery of traditional Chinese Gingko Biloba extract EGb-761 and bilobalide BN-52021 induces superior neuroprotective effects on pathophysiology of heat stroke. Prog Brain Res. 2021; 265: 249-315. http://doi.org/10.1016/bs.pbr.2021.06.007.
28. Sereda M, Xia J, Scutt P et al. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. 2022; 11(11): CD013514. http://doi.org/10.1002/14651858.CD013514.pub2.
29. Evans JR. Ginkgo biloba extract for age-related macular degeneration. Cochrane Database Syst Rev. 2013; 2013(1): CD001775. http://doi.org/10.1002/14651858.CD001775.pub2.
30. Mei N, Guo X, Ren Z et al. Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017; 35(1): 1-28. http://doi.org/10.1080/10590501.2016.1278298.
31. Azuma F, Nokura K, Kako T et al. An Adult Case of Generalized Convulsions Caused by the Ingestion of Ginkgo biloba Seeds with Alcohol. Intern Med. 2020; 59(12): 1555-8. http://doi.org/10.2169/internalmedicine.4196-19.
32. Thiagarajan G, Chandani S, Harinarayana Rao S et al. Molecular and cellular assessment of ginkgo biloba extract as a possible ophthalmic drug. Exp Eye Res. 2002; 75(4): 421-30.
33. Gakhramanov FS, Kerimov KT, Dzhafarov AI. Use of natural antioxidants for the correction of changes in general and local parameters of lipid peroxidation and antioxidant defense system during experimental eye burn. Bull Exp Biol Med. 2006; 142(6): 696-9. http://doi.org/10.1007/s10517-006-0454-z.
34. Russo V, Stella A, Appezzati L et al. Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis. Eur J Ophthalmol. 2009; 19(3): 331-6. http://doi.org/10.1177/112067210901900301.
35. Fogagnolo P, Romano D, De Ruvo V et al. Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery. J Ocul Pharmacol Ther. 2022; 38(4): 305-10. http://doi.org/10.1089/jop.2021.0123.